Ahrén B, et al. - In the SUSTAIN 1 to 5 trials, researchers evaluated the impact of baseline body mass index (BMI) and the incidence of nausea and/or vomiting on weight loss induced by semalgutide. For this analysis, patients with inadequately controlled type 2 diabetes (drug-naïve or on background treatment) were randomly allocated to subcutaneous semaglutide 0.5 mg (excluding SUSTAIN 3), 1.0 mg (all trials), or a comparator (placebo, sitagliptin, exenatide extended release or insulin glargine). Regardless of baseline BMI, semaglutide-induced weight loss was consistently greater vs comparators. Nausea or vomiting was only a minor contribution to this weight loss.